BIOCON - Biocon | Wealthrox

Biocon

BIOCON · Pharma > Pharmaceuticals & Drugs · Chairman: Kiran Mazumdar-Shaw · MD: Siddharth Mittal · Listing date: April 8, 2004 · Employees: 13500 · Bangalore · http://www.biocon.com

Stock Price vs Company Growth

0.9%

1.7%

12.2%

8.2%

7.6%

26.9%

4.4%

10y

17.5%

all

14.9%

🤔 How to analyze this graph?

Last Traded Price

₹ 342 0.9%

291

405

Company Overview

Sales

14,762 Cr

Growth: 10.5%

Profit after Tax

728 Cr

Growth: -46.5%

Large Cap

41,091 Cr

P/E: 50.9x

Industry P/E: 32.5x

Fundamentals

Sales (Cr)	₹ 14,762
Growth	10.5%
EBITDA	20.1%
P/S	2.8x
Dividend	0.1%
P/E	50.9x
Book Value	₹ 170
PEG Ratio	4.8x
ROE	3.6%
P/B	2.0x

Shareholding Pattern

Institutions

Life Insurance Corporation Of India (Lic)

4.11 %

Ahan- I Ltd

1.66 %

Qualified Institutional Buyer

0.61 %

Promoters

Kiran Mazumdar Shaw

39.62 %

Glentec International

19.76 %

John Mccallum Marshall Shaw

0.7 %

Ravi Rasendra Mazumdar

0.4 %

Yamini R Mazumdar

0.11 %

Others

Arun Suresh Chandavarkar

1.1 %

Beneficial Holdings Under Mgt-4

0.46 %

Iepf

0.01 %

Increase Decrease No change

Company Profile Detailed

The company is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development.

Belongs to (33 Indices) view more

Investors (373)

mahesh.g...

syed.sal...

rakesh.k...

Followers (42)

kiran198...

deepak

nitin2